UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in insulin- naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial

Diabetes & metabolism, 2017-09, Vol.43 (4), p.351-358

2017

Volltextzugriff (PDF)

Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus

Diabetes & metabolism, 2013-12, Vol.39 (6), p.485-496

2013

Volltextzugriff (PDF)

Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension)

Diabetes & metabolism, 2017-10, Vol.43 (5), p.446-452

2017

Volltextzugriff (PDF)

GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials

Diabetes & metabolism, 2015-12, Vol.41 (6), p.6S16-6S20

2015

Volltextzugriff (PDF)

Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application

Diabetes technology & therapeutics, 2008-10, Vol.10 (5), p.333-349

2008

Volltextzugriff (PDF)

The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation

Diabetes & metabolism, 2016-04, Vol.42 (2), p.77-79

2016

Volltextzugriff (PDF)

Different insulin concentrations in resuspended vs. unsuspended NPH insulin: Practical aspects of subcutaneous injection in patients with diabetes

Diabetes & metabolism, 2018-09, Vol.44 (4), p.368-372

2018

Volltextzugriff (PDF)

Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: A dose–response study

Nutrition, metabolism, and cardiovascular diseases, 2014-07, Vol.24 (7), p.709-716

2014

Volltextzugriff (PDF)

Early insulin treatment in type 2 diabetes: ORIGINal sin or valuable choice as ORIGINal treatment? An open debate on the ORIGIN study results

Nutrition, metabolism, and cardiovascular diseases, 2012-12, Vol.22 (12), p.1007-1012

2012

Volltextzugriff (PDF)

Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes

Nutrition, metabolism, and cardiovascular diseases, 2009-10, Vol.19 (8), p.571-579

2009

Volltextzugriff (PDF)

Physical characteristics that predict final basal insulin dose in type 2 diabetes mellitus, with a special focus on BMI

Nutrition, metabolism, and cardiovascular diseases, 2014-12, Vol.24 (12), p.1354-1359

2014

Volltextzugriff (PDF)

IDF2022-1166 Response to glargine U-100 initiation in new subgroups of type 2 diabetes replicated in randomised controlled trials

Diabetes research and clinical practice, 2023-03, Vol.197, p.110339, Article 110339

2023

Volltextzugriff (PDF)

Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes

Diabetes & metabolism, 2018-02, Vol.44 (1), p.15-21

2018

Volltextzugriff (PDF)

Successful use of insulin glargine during entire pregnancy until delivery in six Type 1 diabetic women

European journal of obstetrics & gynecology and reproductive biology, 2007-06, Vol.132 (2), p.238-239

2007

Volltextzugriff (PDF)

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes

Diabetes & metabolism, 2020-04, Vol.46 (2), p.110-118

2020

Volltextzugriff (PDF)

Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) – a review of evidence and clinical interpretation

Diabetes & metabolism, 2019-09, Vol.45 (4), p.330-340

2019

Volltextzugriff (PDF)

Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naïve type 2 diabetes: Design and population

Nutrition, metabolism, and cardiovascular diseases, 2019-05, Vol.29 (5), p.496-503

2019

Volltextzugriff (PDF)

Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events

Diabetes & metabolism, 2018-09, Vol.44 (4), p.333-340

2018

Volltextzugriff (PDF)

Female Sex and Angiotensin-Converting Enzyme (ACE) Insertion/Deletion Polymorphism Amplify the Effects of Adiposity on Blood Pressure

Hypertension (Dallas, Tex. 1979), 2022-01, Vol.79 (1), p.36-46

2022

Volltextzugriff (PDF)

Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial

Diabetes & metabolism, 2017-09, Vol.43 (4), p.351-358

2017

Volltextzugriff (PDF)

Corrigendum to “Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naïve type 2 diabetes: Design and population” [Nutr Metabol Cardiovasc Dis 29 (5) (May 2019) 496–503]

Nutrition, metabolism, and cardiovascular diseases, 2019-08, Vol.29 (8), p.869-870

2019

Volltextzugriff (PDF)

Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes

Diabetes & metabolism, 2018-02, Vol.44 (1), p.15-21

2018

Volltextzugriff (PDF)

Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes

Diabetes, obesity & metabolism, 2011-03, Vol.13 (3), p.251-257

2011

Volltextzugriff (PDF)

Use of the short-acting insulin analogue lispro in intensive treatment of Type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal

Diabetic medicine, 1998-07, Vol.15 (7), p.592-600

1998

Volltextzugriff (PDF)

Glucagon: The effects of its excess and deficiency on insulin action

Nutrition, metabolism, and cardiovascular diseases, 2006-03, Vol.16, p.S28-S34

2006

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(31)

Sprache

Englisch
(31)
Japanisch
(3)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in insulin- naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial

Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus

Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension)

GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials

Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application

The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation

Different insulin concentrations in resuspended vs. unsuspended NPH insulin: Practical aspects of subcutaneous injection in patients with diabetes

Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: A dose–response study

Early insulin treatment in type 2 diabetes: ORIGINal sin or valuable choice as ORIGINal treatment? An open debate on the ORIGIN study results

Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes

Physical characteristics that predict final basal insulin dose in type 2 diabetes mellitus, with a special focus on BMI

IDF2022-1166 Response to glargine U-100 initiation in new subgroups of type 2 diabetes replicated in randomised controlled trials

Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes

Successful use of insulin glargine during entire pregnancy until delivery in six Type 1 diabetic women

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes

Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) – a review of evidence and clinical interpretation

Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naïve type 2 diabetes: Design and population

Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events

Female Sex and Angiotensin-Converting Enzyme (ACE) Insertion/Deletion Polymorphism Amplify the Effects of Adiposity on Blood Pressure

Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial

Corrigendum to “Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naïve type 2 diabetes: Design and population” [Nutr Metabol Cardiovasc Dis 29 (5) (May 2019) 496–503]

Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes

Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes

Use of the short-acting insulin analogue lispro in intensive treatment of Type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal

Glucagon: The effects of its excess and deficiency on insulin action

Suchergebnisse filtern